Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4116 | Two doses of placebo at the routine vaccination schedule Wiki | 1.00 |
| drug4104 | Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule Wiki | 1.00 |
| drug4115 | Two doses of placebo at the emergency vaccination schedule Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4105 | Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule Wiki | 1.00 |
| drug4110 | Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule Wiki | 1.00 |
| drug2029 | Ivermectin Wiki | 0.21 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ/Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research & Development Co., Ltd. The purpose of this study is to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults aged 18~59 Years.
Description: Occurence of adverse reactions post vaccination
Measure: Safety indexes of adverse reactions Time: From the beginning of the vaccination to 28 days after the whole schedule vaccinationDescription: The seroconversion rates of neutralizing antibodies against 2019 novel coronavirus tested by micro-neutralization assay in serum
Measure: Immunogenicity indexes of neutralizing-antibody seroconversion rates for the emergency vaccination schedule （day 0,14） Time: The 14th day after two doses of vaccinationDescription: The seroconversion rates of neutralizing antibodies against 2019 novel coronavirus tested by micro-neutralization assay in serum
Measure: Immunogenicity indexes of neutralizing-antibody seroconversion rates for the routine vaccination schedule (day 0,28) Time: The 28th day after two doses of vaccinationDescription: Occurence of adverse reactions post vaccination
Measure: Safety indexes of adverse reactions Time: 0~7 days after each dose injectionDescription: Safety index, abnormal changes will be defined as any one of the lab indexes experiencing changes out of clinical reference value range.
Measure: Occurrence of abnormal changes of laboratory safety examinations (hemoglobin,WBCs, platelets, ALT, AST, total bilirubin, creatinine, creatine phosphokinase, urine protein, urine sugar, urinary erythrocyte) Time: The 3rd day after each dose injectionDescription: Occurence of SAEs post vaccination
Measure: Safety indexes of serious adverse events (SAEs） Time: From the beginning of the vaccination to 6 months after two doses of vaccinationDescription: The seroconversion rates of neutralizing antibodies against 2019 novel coronavirus tested by micro-neutralization assay in serum
Measure: Immunogenicity indexes of neutralizing-antibody seroconversion rates Time: 7,14,21,42 days after the first dose injection for emergency vaccination schedule and 28,35,42 days after the first dose injection for the routine vaccination schedulesDescription: The seropositivity rates of IgG antibody tested by ELISA serum
Measure: Immunogenicity indexes of IgG antibody seropositivity rates Time: 7,14,21,28, 42 days after the first dose injection for emergency vaccination schedule and 28,35,42,56 days after the first dose injection for the routine vaccination scheduleDescription: The seropositivity rates of IgM antibody tested by ELISA serum
Measure: Immunogenicity indexes IgM antibody seropositivity rates Time: 7,14,21,28, 42 days after the first dose injection for emergency vaccination schedule and 28,35,42,56 days after the first dose injection for the routine vaccination scheduleDescription: The GMT of neutralizing antibody against 2019 novel coronavirus tested by micro-neutralization assay in serum
Measure: Immunogenicity indexes of GMT of neutralizing-antibody Time: 7,14,21,28, 42 days after the first dose injection for emergency vaccination schedule and 28,35,42,56 days after the first dose injection for the routine vaccination scheduleDescription: The GMR of neutralizing antibody against 2019 novel coronavirus tested by micro-neutralization assay in serum
Measure: Immunogenicity indexes of GMR of neutralizing-antibody Time: 7,14,21,28, 42 days after the first dose injection for emergency vaccination schedule and 28,35,42,56 days after the first dose injection for the routine vaccination scheduleDescription: specific cellular immune responses
Measure: Immunogenicity indexes of cellular immune Time: The 14th day after each dose vaccinationDescription: he seropositivity rates of neutralizing antibodies against 2019 novel coronavirus tested by micro-neutralization assay in serum
Measure: Immunogenicity indexes of neutralizing-antibody persistence Time: 6 months after two doses of vaccinationDescription: The GMT of neutralizing antibody against 2019 novel coronavirus tested by micro-neutralization assay in serum
Measure: Immunogenicity indexes of neutralizing-antibody GMT Time: 6 months after two doses of vaccinationDescription: Seropositivity rates of antinuclear antibody in serum
Measure: Safety indexes-Seropositivity rates of antinuclear antibody Time: The 7th day after each dose injectionDescription: Level of Inflammatory factors in serum
Measure: Safety indexes-Level of Inflammatory factors Time: The 7th day after each dose injectionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports